DNAM-1-based  	DNAM-1-based  	 FW	B-NP
chimeric  	chimeric  	 FW	I-NP
antigen  	antigen  	 FW	I-NP
receptors  	receptors  	 FW	I-NP
enhance  	enhance  	 FW	O
T  	T  	 FW	B-NP
cell  	cell  	 FW	I-NP
effector  	effector  	 FW	I-NP
function  	function  	 FW	I-NP
and  	and  	 CC	O
exhibit  	exhibit  	 NN	B-NP
in  	in  	 IN	O
vivo  	vivo  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
against  	against  	 IN	O
melanoma  	melanoma  	 FW	B-NP
Chimeric  	Chimeric  	 FW	I-NP
antigen  	antigen  	 FW	I-NP
receptor  	receptor  	 FW	I-NP
( 	( 	 -LRB-	O
CAR 	CAR 	 NNP	B-NP
)  	)  	 -RRB-	O
T  	T  	 NN	B-NP
cell  	cell  	 NN	I-NP
therapies  	therapies  	 NNS	I-NP
hold  	hold  	 VBP	O
great  	great  	 JJ	O
potential  	potential  	 NN	O
for  	for  	 IN	O
treating  	treating  	 VBG	B-NP
cancers 	cancers 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
new  	new  	 JJ	O
CARs  	CARs  	 NN	O
that  	that  	 WDT	O
can  	can  	 MD	O
target  	target  	 VB	O
multiple  	multiple  	 JJ	O
tumor  	tumor  	 NN	B-NP
types  	types  	 NNS	I-NP
and  	and  	 CC	O
have  	have  	 VB	O
the  	the  	 DT	O
potential  	potential  	 JJ	O
to  	to  	 TO	O
target  	target  	 VB	O
non-hematological  	non-hematological  	 JJ	B-NP
malignancies  	malignancies  	 NNS	I-NP
are  	are  	 VBP	O
needed 	needed 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
study 	study 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
tumor  	tumor  	 NN	B-NP
recognition  	recognition  	 NN	I-NP
ability  	ability  	 NN	I-NP
of  	of  	 IN	O
a  	a  	 DT	O
natural  	natural  	 JJ	O
killer  	killer  	 NN	O
cell-activating  	cell-activating  	 JJ	O
receptor 	receptor 	 NN	B-NP
,  	,  	 ,	O
DNAM-1  	DNAM-1  	 NNP	B-NP
was  	was  	 VBD	O
harnessed  	harnessed  	 VBN	O
to  	to  	 TO	O
design  	design  	 VB	O
CARs  	CARs  	 JJ	O
that  	that  	 IN	O
target  	target  	 NN	O
multiple  	multiple  	 JJ	O
tumor  	tumor  	 NN	B-NP
types 	types 	 NNS	I-NP
.  	.  	 .	O
DNAM-1  	DNAM-1  	 NNP	B-NP
ligands 	ligands 	 NN	I-NP
,  	,  	 ,	O
PVR  	PVR  	 NNP	B-NP
and  	and  	 CC	O
nectin-2 	nectin-2 	 NNP	B-NP
,  	,  	 ,	O
are  	are  	 VBP	O
expressed  	expressed  	 VBN	O
on  	on  	 IN	O
primary  	primary  	 JJ	B-NP
human  	human  	 JJ	I-NP
leukemia 	leukemia 	 NN	I-NP
,  	,  	 ,	O
myeloma 	myeloma 	 NN	B-NP
,  	,  	 ,	O
ovarian  	ovarian  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
,  	,  	 ,	O
melanoma 	melanoma 	 NN	B-NP
,  	,  	 ,	O
neuroblastoma 	neuroblastoma 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
Ewing  	Ewing  	 NNP	B-NP
sarcoma 	sarcoma 	 NN	I-NP
.  	.  	 .	O
DNAM-1  	DNAM-1  	 NNP	B-NP
CARs  	CARs  	 JJ	I-NP
exhibit  	exhibit  	 NN	I-NP
high  	high  	 JJ	O
tumor  	tumor  	 NN	B-NP
cell  	cell  	 NN	I-NP
cytotoxicity  	cytotoxicity  	 NNS	I-NP
but  	but  	 CC	O
low  	low  	 JJ	O
IFN-γ  	IFN-γ  	 JJ	B-NP
secretion  	secretion  	 NN	I-NP
in  	in  	 IN	O
vitro 	vitro 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
contrast  	contrast  	 NN	O
to  	to  	 TO	O
other  	other  	 JJ	O
CAR  	CAR  	 NN	O
designs 	designs 	 NNS	O
,  	,  	 ,	O
co-stimulatory  	co-stimulatory  	 JJ	B-NP
domains  	domains  	 NN	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
improve  	improve  	 VB	O
the  	the  	 DT	O
expression  	expression  	 NN	O
and  	and  	 CC	O
function  	function  	 NN	O
of  	of  	 IN	O
DNAM-1  	DNAM-1  	 NNP	B-NP
CARs 	CARs 	 NNP	I-NP
.  	.  	 .	O
A  	A  	 DT	O
DNAM-1 	DNAM-1 	 NNP	B-NP
/ 	/ 	 NNP	O
CD3zeta  	CD3zeta  	 NNP	O
CAR  	CAR  	 NNP	O
reduced  	reduced  	 VBD	B-NP
tumor  	tumor  	 JJ	I-NP
burden  	burden  	 NN	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
murine  	murine  	 JJ	B-NP
melanoma  	melanoma  	 JJ	I-NP
model  	model  	 NN	I-NP
in  	in  	 IN	O
vivo 	vivo 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
DNAM-1-based  	DNAM-1-based  	 NNP	B-NP
CARs  	CARs  	 NNP	I-NP
may  	may  	 MD	O
have  	have  	 VB	O
the  	the  	 DT	O
potential  	potential  	 JJ	O
to  	to  	 TO	O
treat  	treat  	 VB	O
PVR  	PVR  	 NNP	B-NP
and  	and  	 CC	O
nectin-2  	nectin-2  	 CD	B-NP
expressing  	expressing  	 CD	I-NP
hematological  	hematological  	 NNS	I-NP
and  	and  	 CC	O
solid  	solid  	 JJ	O
tumors 	tumors 	 NNS	O
.  	.  	 .	O
